Novartis To Sell Flu Vaccine Adjuvant To Korea's Green Cross
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korean vaccine maker Green Cross recently signed a deal with Novartis to buy the latter's adjuvanted A/H1N1 vaccine MF59 to expand Green Cross' A/H1N1 vaccine production volume
You may also be interested in...
Demand For A/H1N1 Vaccine Catapults Green Cross Into No. 2 Spot In Korea; Company Ramps Up Biosimilar Pipeline
SEOUL - Of the many local Korean pharmaceutical players, vaccine producer Green Cross was the biggest beneficiary of the A/H1N1 flu pandemic last year as increased demand for its vaccines triggered a remarkable upgrade in its rankings to the second-largest from its previous long-time position of No. 5
Demand For A/H1N1 Vaccine Catapults Green Cross Into No. 2 Spot In Korea; Company Ramps Up Biosimilar Pipeline
SEOUL - Of the many local Korean pharmaceutical players, vaccine producer Green Cross was the biggest beneficiary of the A/H1N1 flu pandemic last year as increased demand for its vaccines triggered a remarkable upgrade in its rankings to the second-largest from its previous long-time position of No. 5
Korea's Green Cross Gets Green Light From KFDA To Produce Novartis Adjuvanted A/H1N1 Vaccine
SEOUL - South Korean vaccine maker Green Cross said it has received the green light from Korea FDA to use Novartis's MF59 adjuvanted A/H1N1 vaccine for production of an A/H1N1 vaccine